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Introduction the European Union. In North America, no such guide-
lines have been promulgated over the last decade.
Chronic peripheral arterial occlusive disease (PAOD) However, with increasing globalisation, transatlantic
can be regarded as a marker of generalised athero- cooperation in drug research and development is
sclerosis. Patients with intermittent claudication must crucial. Guidelines by definition are not static docu-
be considered a high-risk population for the de- ments, but should reflect the current knowledge. In
velopment of clinical manifestations of cardiovascular order to stimulate this discussion process and to facili-
disease. From a medical and socio-economic point of tate joint U.S.A./European development programmes,
view, the major goals are reduction of cardiovascular a conference was held in Basel, Switzerland on 15–17
morbidity and mortality, improvement of PAOD November 1997, to discuss the scientific background
symptoms, normalisation of mobility, and prevention of PAOD guidelines based on published evidence and
of amputation. Concurrent illness, life style, and life the extensive knowledge of clinical investigators and
expectancy all influence initial treatment decisions for experienced regulators.
intermittent claudication. Current treatment re- The conference was organised by Prof. William R.
commendations are generally conservative and focus Hiatt, University of Colorado Health Sciences Center,
on symptomatic relief through risk-factor modi- Denver, CO, U.S.A., Prof. John A. Dormandy, De-
fication, exercise and, if efficacious, drug treatment. partment of Vascular Sciences, St George’s Hospital,
Percutaneous transluminal angioplasty (PTA) and/or London, U.K., Prof. Kurt A. Jaeger and Dr. Karl-Heinz
bypass surgery may be appropriate in selected cases. Labs, Department of Angiology, University of Basel
In patients with critical limb ischaemia, invasive Medical School, Basel, Switzerland, and Dr. Claus-
vascular intervention is the treatment of choice. How- Steffen Stuerzebecher, Berlin, Germany. Fifty-two ex-
ever, for patients who are not eligible for vascular perts from the U.S.A. and Europe, including rep-
reconstruction and patients with a critical-risk profile, resentatives from Regulatory Authorities, participated.
pharmacological-treatment options may be important. The following text summarises the conclusions of
Over the years, a number of guidelines for the the meeting. It was composed by the Organising Com-
clinical development of drugs for the treatment of mittee of the meeting and based on the transcript of
peripheral vascular disease were developed by special- the meeting’s discussion sessions. However, it must
ist vascular societies and national health authorities. be emphasised that, although the manuscript was
Recently, the European Regulatory Agency issued circulated to and accepted by the participants, the
guidelines, aiming at a harmonisation of the drug content of the paper may not necessarily reflect thedevelopment process at least within the countries of
opinion of all individuals. It is hoped that this paper
may serve as a reference for the development of future
* Please address all correspondence to: K.-H. Labs, Department of transatlantic guidelines for the evaluation of phar-Angiology, University of Basel Medical School, Petersgraben 4,
CH-4031 Basel, Switzerland. macotherapy in PAOD.
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vascular events (i.e. myocardial infarction, ischaemicPart A: Peripheral Arterial Occlusive Disease:
stroke). If there is any evidence of drug toxicity, theFontaine Stage II (Intermittent Claudication)
follow-up should be performed in a double-blind,
controlled rather than an open-label manner.
Prevention trials. CPMP guidelines suggest a minimum
trial duration of[12 months for long-term endpoints,
Study design
General design
such as cardiovascular morbidity and mortality or
Phase III clinical trials should generally follow a ran- progression of atherosclerosis.1 However, in order to
domised, double-blind, parallel-group study design. obtain sufficient event rates and clinical relevance of
Crossover designs should be the exception and may the results, a treatment period of [24 months is
only be acceptable for short trials with short-acting strongly recommended.
drugs, e.g. pharmacokinetic or pharmacodynamic
phase I or II studies, but not for phase III trials.
Placebo control versus active-drug control
Recommendation: Trial designPhase III clinical trials in patients with intermittent
claudication with the walking distance as the primary Claudication trials
outcome measure should generally be placebo-con-
trolled. Active-drug-controlled trials without a placebo • PAOD trials aiming at the claudication distance
arm will be the exception and may only be considered should have a randomised, double-blind,
if the comparator drug has consistently shown su- placebo-controlled, parallel-group design.
periority over placebo in several trials and the mag- • A treatment period of approximately 6 months
nitude of the drug effect has been widely accepted by is generally considered sufficient.
the medical community. The aim of clinical trials using • To exclude a sudden rebound effect, a post-
an active-therapy control may be to demonstrate su- treatment follow-up period of not less than 4
periority or non-inferiority of the experimental drug. weeks should be considered.
An appropriate statistical approach for the study aim • To obtain appropriate safety information the
chosen should be determined a priori. total study time (treatment phase and follow-up
phase) should not be less than 12 months in an
appropriate number of patients.
Duration of treatment and follow-up • If there is evidence of drug toxicity, the follow-up
The duration of treatment will depend on the aim of should be performed in a double-blind, controlled
the study and the endpoint(s) chosen. rather than in an open-label manner.
Prevention trials
Claudication trials. For claudication studies, a period
• For trials aiming at the cardiovascular morbidityof approximately 6 months is generally accepted and
and mortality or at the progression of athero-is in agreement with the guidelines of the European
sclerosis a treatment period of [24 months isUnion (Committee for Proprietary Medicinal Products,
recommended.CPMP).1 The length of exposure to the drug should
be sufficient to ensure that tolerance (if expected) will
not develop.
The duration of the post-treatment follow-up period
will also depend on the study goals. With respect to
efficacy in claudication trials, a short follow-up period
(e.g., not less than 4 weeks) is regarded as sufficient Stratification
to demonstrate that no sudden loss in claudication
distance (rebound) occurs. Uneven distribution of potential but unknown con-
founders, such as cardiovascular risk factors, haemo-With respect to safety, long-term experience is re-
quired to demonstrate that the clinical benefit of the dynamic parameters, demographic variables, and
others can usually be avoided by an appropriate ran-compound outweighs the risks. This holds particularly
true for PAOD patients, with their high risk of cardio- domisation process and an adequate sample size.
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Stratification reduces the risk of an imbalance be- Run-in phase and testing for baseline stability
(Note: The following sections, up to and includingtween study groups and may bias results and
Physical training, refer to claudication trials only)diminishes the need to adjust data post hoc. However,
these gains may be modest in comparison with the
It is commonly known that walking distance maydisadvantages of complicating both patient re-
vary with mood, motivation, temperature, and othercruitment and data analysis. In general, a pre-
environmental factors. The larger this ‘‘backgroundrandomisation stratification is recommended: (a) if
noise’’, the more difficult it will be to demonstrate drugthe hypothesis whether a drug is particularly ef-
efficacy, particularly for only moderately effectiveficacious in an identifiable subgroup of patients is
compounds. In order not to unduly inflate the sizeto be tested, or (b) if one or more of the patient
of the patient sample needed, European Unionbackground characteristics are known to be strong
(CPMP) guidelines1 recommend that patients withindependent predictors of outcome.
pronounced baseline variability in claudication dis-The occurrence of slight imbalances in the dataset
tance be excluded (the absolute claudication distancecan be handled by post hoc (analytic) adjustment, pro-
should not vary by more than 25% when testedvided that the adjustment for the effects of predefined
twice on a treadmill over a three- to six-week run-and covariables is prospectively planned and specified
in period).in the study protocol.
However, there is no published evidence that vari-However, in claudication trials, there is usually
ability prior to entry translates into higher variabilityno need for stratification. The clinical suspicion that
during and at the end of the study. Insistence on theclaudicants with diabetes mellitus respond to drug
stability of the absolute claudication distance (ACD) attreatment differently to those without diabetes has
baseline results in a loss of[20% of patients otherwisenot been substantiated in clinical trials; thus, strat-
fulfilling the study inclusion criteria, and also conflictsification is not required even for diabetics, as long
with the rule that the study sample should be repres-as patients with clinically severe diabetic neuropathy
entative of a general PAOD stage II population (studyare excluded; the latter is required, as this com-
sample representativity).plication interferes with the assessment of the clau-
It is recommended: (a) to include only patients indication distances ACD (=absolute claudication
whom the diagnosis of stage II PAOD is establisheddistance) and ICD (=initial claudication distance).
for [6 months, (b) to exclude patients who haveIn prevention trials the situation is different. There
a recognised potential for instability (differences inis evidence from studies using antiplatelet agents in
claudication distances between days, recent phasespatients with diabetes mellitus and vascular disease
of deterioration or improvement, recent surgical orthat less (rather than more) man-years of treat-
endovascular intervention), and (c) to limit the studyment are required to prevent fatal cardiovascular
run-in phase to two or three treadmill tests for theevents than for non-diabetic patients with vascular
purpose of treadmill test familiarisation.disease.2,3 Thus, stratification for diabetes mellitus
However, a counter-argument was proposed to(or separate trials for diabetics) is recommended.
maintain the treadmill variabilityZ25% as an entry
criterion. This would ensure a more reproducible
measure of ACD, which would in turn require fewer
patients to reach statistical significance in a clinical
trial. The decision to define criteria for baseline tread-
mill-test variability should be left to the investigatorsRecommendation: Stratification
and the sponsors responsible for a particular trial. The
issues are the anticipated magnitude of drug effect,• Present knowledge does not indicate that
the variability of the treadmill methodology, and thestratification in clinical trials in intermittent
stability of the population enrolled in the study. Allclaudicants is usually required, unless there is
of these issues will affect sample size.strong evidence that independent predictors of
Regarding other variables potentially influencingoutcome (other than the trial endpoint) exist, or
the claudication distance, therapeutic strategies shouldif a hypothesis that the drug is efficacious only
be set and not changed during the course of thein specific patient subgroups is being tested.
study. These variables include lipid-lowering therapy,• For prevention trials diabetics should be stratified
or tested in a separate study. anticoagulation, smoking, exercise, changes in body
weight, and others. However, there is no good reason
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for withholding life-style counselling from patients for prerandomisation stratification of the patient
sample (see Stratification section, on page 254). Euro-(particularly on smoking, even if smoking is stopped
after initiation of the trial). pean Union guidelines1 stipulate that the ACD range
at baseline should be limited to 100–300 m, the
reason for the lower limit being that the clinical
prognosis of patients with more severe disease may
differ from that of patients with a lesser degree of
PAOD. There are a number of variables which areRecommendations: Stability of baseline
associated with the prognosis, including peripheralclaudication distance
haemodynamics such as the ankle pressures and the
ABPI.4–8 However, these variables correlate poorly• Patients who by history have a recognised
with the patient’s walking ability.9–13 Consequently,potential for instability should be excluded, and
there is little scientific justification for defining afactors potentially influencing the claudication
lower end of a claudication distance range. Still,distance should be kept constant during the
further clinical-trial data on the behaviour of thesecourse of the study.
markedly disabled patients with claudication would• Testing for stability of claudication distance
be desirable.during a study run-in phase should not be
The reason for the upper limit (300 m) relates tomandatory; the question of whether to include
the increased frequency of a walking-through phe-stability testing or not should be left to the
nomenon known to occur with longer claudicationdecision of investigators and sponsors of a
distances.15 However, this is a problem specificallyparticular trial. To include stability testing will
related to constant-workload treadmill protocols.increase the precision, reduce the baseline
With graded treadmill protocols, workload is in-variance and decrease the sample size; to omit
creased until the maximum walking capacity isstability testing will increase the enrolment of
reached; thus, walking-through phenomena arepatients and improve the generalisability of the
avoided.15,16study results.
Physical training
Selection of patients
The therapeutic value of a structured, organised, and
supervised physical training programme cannot beInclusion and exclusion criteria should warrant that
doubted.14,17 However, there are few such programmesthe patient sample is representative of a general PAOD
available, and there is published evidence that thepopulation.
willingness of patients to participate is limited.18
Patients already participating or intending to enrol in
a supervised physical-group-training class should be
excluded from clinical trials unless the study protocolInclusion criteria
defines that all patients from both groups will par-
ticipate.Inclusion criteria for PAOD stage II trials are broadly
accepted and are well described in the current The value of non-supervised physical training
is less clear. As with all other factors potentiallyEuropean Union (CPMP) guidelines.1 Claudication
should be stable and should have been present for influencing the claudication distance (see Run-in
phase and testing for baseline stability section, on page[6 months, the diagnosis of PAOD established
and confirmed by haemodynamic measurements 255), decisions should be made and strategies should
be set prior to initiation of a clinical trial, and these(ankle–brachial pressure index, ABPI <0.90); the
location of the lesion(s) should be documented by should not be changed during the course of the
study. It may also be recommended that in orderduplex sonography or angiography. Patients with a
recognised potential for claudication instability to allow for a potentially necessary adjustment for
different levels of physical activity, the type, fre-should be excluded (see Run-in phase and testing for
baseline stability section, on page 255). In trials aiming quency and intensity of any home-based training
may be documented in the case record form.at the claudication distance there is usually no reason
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of the patient. Treatment of claudication should
improve the maximum physical capacity of the patientRecommendation: Selection of patients
and therefore would serve as the endpoint. From a
clinical point of view, ICD may be the more important• The diagnosis of PAOD must be established
variable, since patients seldom force themselves to theclinically and confirmed haemodynamically, and
extreme of ACD. On the other hand, ICD is morethe location of lesions should be documented.
subjective. In addition to the question of clinical rel-• Intermittent claudication should be stable and
evance (the answer to which may remain open), theshould have been present for at least 6 months.
reproducibility of ICD and ACD is an issue. There is• Patients participating or intending to enrol in
published evidence that the reproducibility of thestructured, organised, supervised physical train-
two parameters varies with the treadmill protocoling programmes should be excluded unless the
used.15,16,22–27 With constant-load treadmill protocols,protocol defines that all patients from both groups
the reproducibility of ICD and ACD is similar, whereaswill participate.
with graded protocols ACD is superior to ICD. Con-• Strategies for a home-based training programme
sequently, ACD may be given preference over ICD asshould be set prior to enrolment into a clinical
the primary endpoint; this decision would allow ittrial and should not be changed during the course
to be independent of the treadmill protocol but isof the study. This also applies to all other factors
mandatory if a graded test is used.that may potentially influence the patient’s
walking performance.
Assessment of the claudication distance: Constant-workload
versus graded-workload treadmill testing. The preferred
method to assess claudication distances is treadmill
testing. There are two internationally accepted tread-
mill protocols, i.e. the constant-workload protocol
using a constant speed and grade (mostly 2 mph=
3.2 km/h; and 12% grade), and the graded test where
Outcome measures
Primary endpoints
the speed is kept constant but the grade is varied,Since the key symptom of PAOD stage II is intermittent
starting horizontally but then increasing in predefinedclaudication, claudication distance on the treadmill
steps (e.g. 2%) at predefined intervals (e.g. 2 min).should be the primary endpoint. The decision to use
The two tests differ, in that the relationship betweentreadmill testing for the assessment of claudication
workload and walking time follows a linear functiondistances is merely related to a non-acceptable variance
with the constant test but a curvilinear function withof results from other possible alternative testing
the graded test.15,28 This curvilinear relationship ex-methods. It should, however, be emphasised in this
plains the main advantages of the graded test: (a) acontext that treadmill-test results markedly under-
low workload in the early test phase allows properestimate the patient’s walking ability under daily-life
differentiation of patients with differing highly limitedconditions.
walking distances and (b) the continuously increasingCardiovascular morbidity and mortality represent
workload in late test stages avoids the occurrence ofthe main risk associated with stage II PAOD.4,5,19–21
a walking-through phenomenon.Prevention studies represent an entirely different cat-
The reproducibility of the two tests is comparable,egory of clinical trials and thus require an entirely
except with rather short claudication distances (e.g.different study design. From a clinical and an eco- Z100 m, as measured with the constant load test). Innomical point of view, this type of study may even be
these cases, the graded test is superior to the constantmore important than trials, merely focusing on the
load test.28 Both tests can be equally recommended forpatient’s walking ability.
use in clinical trials, although, if either very short or
rather long claudication distances are to be tested, the
graded test should be preferred. However, at presentInitial claudication distance versus absolute claudication
distance there is still limited experience with the analysis of
graded-treadmill data, particularly regarding the non-European Union guidelines1 recommend the use of
the initial claudication distance (ICD) or both the linear relationship of cumulative workload applied
and the outcome measure that is the claudicationinitial and the absolute claudication distance (ACD)
as primary endpoints in claudication trials. In the distance or the time walked on the treadmill. It is also
known that both types of treadmill tests are highlyU.S.A., ACD is preferred over ICD. This is because
the ACD is felt to define the maximal exercise capacity reproducible when performed in laboratories that have
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expertise in treadmill testing in a PAOD population. Quality of life as an endpoint
PAOD represents just one (peripheral) manifestation ofThe reproducibility will be worse in centres with less
familiarity with this form of exercise-testing. a generalised atherosclerotic process. Usually, affected
patients have multiple morbidities, and the assessment
of quality of life (QoL) may give a more representativePrevention studies: morbidity and mortality. The main
picture of the patient’s perception of health than therisk for PAOD patients is related to ischaemic cardio-
exclusive measurement of walking performance. Thus,vascular events. An adequate endpoint in prevention
QoL may be a good primary endpoint for clinical trialsstudies is a composite endpoint comprising non-fatal
in patients with intermittent claudication. Multipleischaemic stroke, myocardial infarction, cardio-
QoL instruments have been used in PAOD patients.vascular death, and potentially coronary and carotid
These include specific scales such as the Peripheralrevascularisation and major amputation, whichever
Arterial Disease – Walking Impairment Questionnaireoccurs first. In order to clarify the terminology, ref-
(PAD–WIQ), the Peripheral Arterial Disease – Physicalerence is made to the WHO criteria for the diagnosis
Activity Recall Questionnaire (PAD–PAR), the Claudi-of coronary events and strokes (fatal and non-fatal).
cation Scale (CLAU-S), and the Periphere ArterielleIn the optimal case, total mortality may be the most
Verschlusskrankheit 86 Scale (PAVK 86), but also non-relevant clinical endpoint; however, this poses prob-
specific instruments such as the Medical Outcomelems of feasibility because of the need for large patient
Study SF 36 (MOS-SF36), the Nottingham Health Pro-numbers. Combining non-fatal cardiovascular morbid-
file (NHP), the McMaster Health Index Questionnaireity with all-cause mortality reflects a comparison of
(MHIQ), or the European Quality of Life Scale (Euro-unequal entities, and inclusion of non-cardiovascular
Qol). At present, a number of unsettled questionsmorbidity renders clinical trials rather difficult. A
prevent the use of QoL as a primary endpoint. Problemcombination endpoint using cardiovascular morbidity
areas include choosing the most appropriate in-and cardiovascular mortality has been criticised,
strument, proper validation of scales, potential com-because survival, irrespective of the cause of death,
position of endpoints, and the definition of whatis what ultimately matters. Such a concern may be
magnitude of change with a specific QoL scale maymitigated if it can be proved that results for the
be considered clinically relevant. At present, QoLprimary composite endpoint are statistically sig-
should be assessed as a secondary endpoint.nificant, that in the optimal case cardiovascular
mortality is significantly reduced and that the change
in cardiovascular mortality also favourably influences
all-cause mortality. Statistical significance versus clinical relevance
Regarding background treatment with platelet-
The question of statistical significance versus clinicalaggregation inhibitors, reference is made to the section
relevance for changes in claudication distance has beenBackground treatment, on page 261 of this article.
a matter of debate for a long time, without a consensus
ever being reached. This statement also holds for the
Basel conference. Consequently, ongoing discussions
in the medical community on the clinical relevance ofSecondary endpoints
study results seem to be inevitable. This dilemma may
be resolved by including a responder analysis, whereSecondary endpoints should focus on clinically rel-
evant data supporting the study aim. These data may a certain (predefined) percentage of patients must
reach a (predefined) level of improvement. If a clin-include variables describing the haemodynamics of
PAOD (such as data on peripheral flow and pressure) ically non-relevant margin can be defined this non-
relevant difference should not be included within theor markers for thrombotic events (such as platelet-
aggregation and other tests of thrombosis and athero- 95% confidence interval (CI) for the difference of group
means30 (e.g. if a difference of group means of 5% isgenesis) which, due to the fact that they are poorly
correlated to the patient’s walking performance, are considered clinically non-relevant, 5% should not be
included within the 95% CI for the difference of groupnot suitable as primary endpoints.9,13,29 If the primary
endpoint is a composite endpoint, the components means). This concept is currently under discussion
with international regulatory authorities; however, noof this composite endpoint should be evaluated as
individual secondary endpoints. final consensus has yet been reached.
For prevention trials any statistically significantIn claudication trials with the walking distance as
the primary endpoint, data on morbidity and mortality difference for the primary (composite) endpoint, in
the optimal case a significant reduction in themust also be collected for safety reasons.
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cardiovascular mortality, coupled with evidence that Part B: Peripheral Arterial Occlusive Disease:
all-cause mortality is also positively influenced but Fontaine Stages III and IV (Critical Limb
definitely not increased, should be acceptable as being Ischaemia, CLI)
clinically relevant.
For the purpose of PAOD guidelines, only the chronic
but not the acute form of CLI will be considered.Recommendations: Outcome measures
• The primary endpoint will depend on the aim of
the study. For walking-performance studies, the
absolute claudication distance (ACD), measured Definition of PAOD stages III and IV/critical limb
ischaemia and CLI-related riskby treadmill testing, is recommended. Treadmill
testing may be performed using a constant-
Most vascular specialists in continental Europe useworkload or a graded-workload-treadmill
the Fontaine classification to categorise the most severeprotocol, except at the extremes of walking
forms of limb ischaemia. The original Fontaine classi-distance where the graded test should be
fication was based on clinical information only. Thepreferred. For the constant-load test it is of
need for a more objective definition of Fontaine stagesadvantage to use internationally accepted settings,
III and IV (or its Anglo-American equivalent ‘‘criticale.g. a speed of 2 mph (3.2 km/h) and a grade of
limb ischaemia’’) became evident when it was shown12%. The treadmill protocol and treadmill settings
that these patients carry an excessively high risk ofmust not be changed during the course of the
cardiovascular events, amputation, and mortality. Thetrial; also, environmental and all other factors
lack of uniform criteria in reporting the results ofinfluencing the test result (room temperature,
studies in CLI precludes the acquisition of reliable datatiming etc.) and staff members performing the test
and prevents the comparison of efficacy of differentshould be kept constant.
therapeutic strategies. Thus, in order to clarify, specify,• For prevention studies, a composite endpoint
and homogenise the definition of PAOD stages III andincluding cardiovascular mortality and cardio-
IV, a consensus document was devised with the inputvascular morbidity, i.e. fatal and non-fatal myo-
of eight European vascular specialist societies.31,32 CLIcardial infarction and stroke (as defined by
in both diabetics and non-diabetics was defined bythe respective WHO criteria) is appropriate.
either of two criteria: persistent recurrent distal-Convincing study results would demonstrate that
extremity pain at rest requiring analgesics for moresignificant changes in the primary endpoint occur,
than 2 weeks, with an ankle systolic pressure ofthat in the optimal case cardiovascular mortality
Z50 mmHg and/or a toe systolic pressureZ30 mmHg;is significantly reduced, and that all-cause
or ulceration or gangrene of the foot or toes in com-mortality is also favourably influenced.
bination with the haemodynamic criteria listed above.• Secondary endpoints should focus on additional
Furthermore, variables describing the comprisedclinically relevant data supporting the study aim.
microcirculation (such as a tcpO2Z20 mmHg) were in-If ACD is used as the primary endpoint, ICD
cluded, particularly to be applied in patients with un-should serve as a secondary endpoint. If walking
reliable pressure readings. The justification of thedistance is used as the primary endpoint,
criteria used was based on the correlation between im-information on cardiovascular morbidity and
paired peripheral haemodynamics and the increasedcardiovascular mortality as well as all-cause
risk of cardiovascular events and amputation.4–7mortality should be included for safety reasons.
Recent studies have raised doubts as to whether• Theoretically, QoL could be used as a primary
the ankle- or toe-pressure cut-off points have beenendpoint. However, a number of questions on
correctly chosen and whether the threshold valuesvalidation, sensitivity, and clinical relevance of
were too low.33,34 There is published evidence in-results are still unsolved. At present, QoL should
dicating a comparable incidence of a combined end-be assessed only as a secondary endpoint.
point of amputation and cardiovascular death in• The question of the clinical relevance of clau-
placebo-treated patients with peripheral pressuresdication distance changes remains unresolved.
below 50 mmHg and those with peripheral pressuresThe definition of a clinically unimportant margin,
below 60 mmHg and/or an ABI <0.60.33 Comparablewhich should not be included into the 95% con-
findings regarding ulcer-healing and amputation werefidence interval for the difference of group means,
reported elsewhere.35,36 Conversely, patients with peri-may be potentially useful.
pheral pressures clearly below CLI threshold who did
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not experience pain at rest or ischaemic skin lesions Study design
have been described in the literature.37
There is undoubtedly a general association between Due to the nature and progression of the disease, only
double-blind, randomised, parallel-group trials arecardiovascular risk, amputation and peripheral pres-
sures. It is of primary value to describe the population appropriate (cross-over designs are not acceptable).
Proper randomisation will ensure an equal distributionat risk with the highest possible sensitivity and speci-
ficity. The second CLI Consensus Conference32 used a of risk factors and patient background characteristics
between the treatment groups. The treatment of con-pressure cut-off of 50 mmHg for this purpose which,
as shown by recent experience,33,34 may be doubted. comitant diseases should be continued throughout
the trial; a protocol-defined standard regimen for theThe problem is that the optimal cut-off is not known
and that the best at present is to give a pressure range treatment of concomitant diseases is not feasible, par-
ticularly in multicentre, multinational trials. However,(50–70 mmHg). The higher the pressure cut-off chosen
the higher will be the sensitivity, but the lower the such standardisation of a concomitant medication
regimen is not required if an appropriate random-specificity, for the description of risk. For clinical trials
using the upper end of the range will increase the isation procedure is used.
study’s inclusivity and thus the availability of patients,
but will decrease the cardiovascular-event rate as well
as the amputation rate. Using the lower end of the Duration of treatment and follow-up
range will result in a narrower (exclusive) set of study
criteria with high patient-sample homogeneity and a The duration of treatment will be determined by the
higher event rate, but reduced patient enrolment. Some pharmacological and toxicological profile and the
reasons for the uncertainty of the correct choice of the mode of action of the drug under investigation. The
right pressure cut-off are related to problems with overall duration of the trial will also depend on the
the accuracy of measuring peripheral pressures non- endpoint(s) selected. While a total of Z6 months may
invasively, particularly in diabetics, chronic renal be appropriate as a treatment and follow-up period
patients, patients with chronic steroid treatment, and for ulcer healing, the assessment of limb salvage rates
the elderly (>80 years). Under these circumstances it requires a longer period of time (i.e. [12 months).
remains an open question whether one fixed cut-off A short run-in phase of 3–4 days should provide
point can be defined at all. At present, reflecting the evidence that the disease is roughly stable (i.e. that
above discussion and until further data are available, there is no rapid improvement or deterioration). In the
regulators suggest stratifying CLI patients with respect majority of cases, a wash-out period is not considered
to pressure ranges (e.g. ankle pressure Z50 mmHg necessary; however, if the previous treatment included
versus 50 mmHg Zankle pressure Z70 mmHg; or a drug prohibited by the study protocol, a short wash-
alternatively toe pressure Z30 mmHg versus out period (of 2–3 days) is recommended.
30 mmHg Ztoe pressure Z50 mmHg), and to report
the results of clinical trials accordingly.
Stratification
Special stratification procedures are generally not re-Recommendation: Definition of critical limb
ischaemia quired. The exception may be diabetes mellitus. There
is no clear evidence from the literature that diabetics
react differently to drug treatment than do non-• Recent studies suggest that the haemodynamic
threshold values used in the CLI consensus diabetics.38–40 On the other hand, it may be argued
that the pathophysiology of diabetic PAOD (wheredocument may have to be reconsidered; final
agreement on this issue has not yet been reached. microangiopathy and neuropathy potentially play a
major role) differs from PAOD caused solely by athero-• At present, it is suggested that the CLI patient
sample be stratified according to baseline sclerosis. In view of these differences in patho-
physiology, and in agreement with European Unionpressure ranges (i.e. ankle pressure Z50 mmHg
versus 50 mmHg Zankle pressure Z70 mmHg; guidelines,1 it is suggested that diabetics and non-
diabetics should be stratified, particularly if the studyor alternatively toe pressure Z30 mmHg versus
30 mmHg Ztoe pressure Z50 mmHg), and to endpoint includes the limb salvage rate, cardiovascular
morbidity and mortality, and/or quantification of thereport study results accordingly.
progression of atherosclerosis.
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Placebo-controlled versus active-therapy-controlled trials • For trials in ulcer healing, a cumulative
treatment/follow-up period of Z6 months may
Based on the European Union guidelines,1 a double- be appropriate, whereas trials on limb-salvage
rates require a longer period of time (i.e. [12blind, placebo-controlled trial design is a standard
requirement. However, if there is a comparator drug months).
• Run-in phases may be as short as 3–4 days andwhich has consistently been proven to be superior to
placebo and has shown convincing efficacy, an active- should provide some evidence of disease stability.
• Wash-out periods are normally not required, buttherapy-controlled trial may be considered. The aim
of clinical trials using an active-therapy control may a short wash-out of 2–3 days may be advisable
if patients had previously received a drugbe to demonstrate superiority or non-inferiority of the
experimental drug. An appropriate statistical approach prohibited by the study protocol.
• With the exception of diabetes, prerandomisationfor the study aim chosen should be predetermined.
stratification is not required if appropriate
randomisation procedures are applied. Minor
imbalances resulting from potential but unknown
confounders in the final dataset can be handled by
adjustment of effects of covariables, if covariablesBackground treatment
were prospectively specified and adjustment
procedures were prospectively planned andThe conference considered the conditions under which
defined in the study protocol.antiplatelet background treatment (in particular with
• Active-drug control may be considered if theacetylsalicylic acid) should be accepted in studies of
comparator drug has consistently been shown toother investigational drugs, if the cardiovascular-event
be superior to placebo, and if the magnitude ofrate is the primary outcome. The effects of antiplatelet
its effect is generally accepted by the medicalagents in preventing cardiovascular morbidity and
community.mortality in PAOD patients have not been evaluated.
• Antiplatelet drugs should be accepted asHowever, meta-analyses of antiplatelet drugs in PAOD
background therapy for both the active and thepatients in combination with those suffering from MI
placebo study arm.and stroke have shown a significant reduction in the
frequency of cardiovascular events during the study
observation period.41,42 Thus, and due to the fact that
PAOD patients are multi-morbid patients with a high
prevalence of coronary heart disease,19,20 there is justi- Patient selection
fication to use antiplatelet drugs as background ther-
In principle, all patients with proven CLI (see Defin-apy in both treatment groups (drug and placebo). If
ition of PAOD stages III and IV, on page 259) in whomantiplatelet agents were used as background ther-
there is no sudden improvement or deterioration (seeapy in a trial aiming at cardiovascular morbidity and
Duration of treatment and follow-up section, on page 260)mortality, there is no general need to later use the
are eligible for CLI trials. European Union guidelines1investigational drug in combination with the back-
stipulate that only those patients who are ineligible forground medication. The question on the value of the
vascular reconstruction should be included. Althoughcombination of the investigational drug and back-
understandable for ethical reasons, this requirementground therapy could only be answered with the help
will result in a selection of end-stage cases in whomof a third study arm of drug+placebo, but without
it is highly unlikely that clinical efficacy of any thera-background treatment.
peutic measure would be demonstrated. A com-
promise could be to accept patients eligible for
reconstruction in clinical trials, as long as the trialRecommendations: Study design
design warrants that surgical or endovascular pro-
cedures are not withheld or unduly delayed; the special• CLI trials should have a randomised, double-
blind, parallel-group design. Cross-over trials are design of these types of studies must be accounted for
in the statistical analysis plan. A lower age-limit of 45not recommended.
• The duration of treatment will differ between years may help to exclude patients suffering from
Buerger’s disease rather than from chronic ath-trials and will depend on the pharmacological
and toxicological profile and the mode of action erosclerotic disease. It is recommended that the dis-
tribution of atherosclerotic lesions be documented byof the study drug.
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duplex sonography or angiography, since these in- (all ulcers epithelialised as assessed by an independent
physician; photographic documentation, even ifvestigations are required for the work-up of CLI
patients and are available in the vast majority of standardised, is considered insufficient). Only
patients with ‘‘flat surface’’ or ‘‘transdermal’’ ulcerscases.
should be admitted. Ischaemic cracks between the
toes or on the heel cannot be used as measurable
endpoints. The ulcer status at baseline may be
documented by measuring the cumulative total ulcer
Recommendations: Patient selection area, e.g. using a dual acetate technique.43 Partial
ulcer-healing or only healing of a reference ulcer is
• The diagnosis of CLI must be established of doubtful clinical relevance and should not be
clinically and confirmed haemodynamically. used as a clinical endpoint.
• Patients eligible for surgical reconstruction can be
included, provided that the study design ensures
that reconstructive and/or endovascular meas-
Amputation. The rate of major amputation (through orures are not withheld or unduly delayed.
above the ankle) can be considered as a primary
endpoint or part of a primary endpoint (see also
Composite endpoints, below). The amputation rate is
usually considered to be one of the ‘‘hardest’’ endpoints
in CLI trials. However, as the criteria for performing
amputation may vary, particularly in multicentre and
multinational studies, the interpretation of study
Endpoints
Primary endpoints
results may be limited. Existing guidelines1 re-
commend that amputation criteria be predefinedCLI patients may suffer from pain at rest, may have
in the study protocol. Even if adhering to thisischaemic lesions, may require amputation, and will
recommendation, rules may sometimes be broken,have an increased risk for cardiovascular morbidity
because the decision to amputate is highly individualand mortality. Thus, the CLI patient should be evalu-
and depends on the patient’s individual risk pattern,ated in a comprehensive fashion. The primary end-
general condition, and other factors. Thus, guidancepoint may focus on pain at rest, ulcer healing, or
included in a protocol will be of limited value andamputation, but all other variables (including cardio-
may introduce a level of pseudo-accuracy not invascular and total mortality) should also be considered,
line with a real-life situation.at least as secondary endpoints. The primary endpoint
Because the underlying cause of CLI is generalisedmay be single, composite or may be based on response
atherosclerosis, both legs (and not only the index leg)criteria.
must be considered for the assessment of amputation
rates.
Single endpoints
Pain at rest. If pain intensity is chosen as a primary
endpoint, it should be assessed objectively, preferably Composite endpoints
by using visual analogue scales. Pain at rest remains Mortality alone, whether cardiovascular or total, is
a soft endpoint influenced by variables such as mood, rarely used as a single primary endpoint in CLI studies.
motivation, and environmental and other factors. Pain In addition to the prevention of death, the status
assessment should always be done by the same as- of the leg is of primary concern. Thus, a composite
sessor at the same time of the day, preferably at endpoint, e.g. amputation and death; or amputation,
the time of trough plasma levels of the drug under systemic morbidity (such as ischaemic stroke and myo-
investigation. Since analgesia is difficult to quantify cardial infarction) and death should be preferred over
and the type and dose of analgesics are likely to change mortality alone.
during the course of the trial, pain relief must be
defined as ‘‘complete relief of pain while off an-
algesics’’.
Response-based endpoints
The trial endpoint may be based on response criteria
and a responder definition applied to both theUlcer-healing. To ensure clinical relevance, ulcer-heal-
ing must be defined as healing of all ulcers of both legs treatment and the placebo/comparator groups, with
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optimal response defined as the patient being alive,
having both legs, having no wound or pain, and being Recommendations: Endpoints
off analgesics. This endpoint concept would allow us
to consider both the time to response as well as the • Conventional primary endpoints acceptable for
duration of response, before the inevitable late-failure clinical trials in CLI include the assessment of
process will occur. As a measure it is suggested to pain at rest (complete relief of pain, off
count the number of ‘‘good days’’, i.e. the time period analgesics), ulcer-healing (complete healing of all
for which the response criterion applies in a given ulcers of both legs), and amputation rates.
follow-up period. Such an approach may be a con- • A composite primary endpoint, including
ceptual step forward. cardiovascular morbidity, amputation and all-
cause mortality may be superior to single primary
endpoints focusing only on CLI symptoms.
• If not used as primary endpoints, cardiovascularSecondary endpoints
morbidity and mortality as well as total mortality
should be assessed individually as secondarySecondary endpoints should focus on clinically rel-
endpoints to ensure the collection of appropriateevant data supporting the study objective. Whatever
safety information.the primary endpoint, information on cardiovascular
• A new endpoint concept based on an optimalmorbidity and mortality, as well as on all-cause
response definition takes into account themortality, must be collected over a sufficiently long
recovery after treatment and the inevitable lateperiod of time (in view of the generally pessimistic
failure and may focus on the number of ‘‘goodprognosis of CLI patients, this will rarely exceed 12
days’’ after recovery (patient alive, both legs, nomonths). If there is legitimate concern that a treatment
wound, no pain, off analgesics).may increase mortality, the study must be powered
• In contrast to intermittent claudication theappropriately to allow for a second estimation of
assessment of QoL is not yet an establishedthe drug’s effect on mortality. If the primary endpoint
endpoint in CLI trial; however, continuedis a composite endpoint, the components of this
evaluation of quality of life instruments iscomposite endpoint should be evaluated individually
important to define appropriate QoL measuresas secondary endpoints.
in CLI patients. At present the assessment of QoL
may be considered as a secondary endpoint.
Quality of life as an endpoint
As with intermittent claudication, the assessment of
QoL would provide a good tool to quantify a
patient’s well-being if sufficiently validated scales Statistical significance versus clinical relevance
were available. QoL instruments have been used in
The question of clinical relevance is less problematicCLI patients and results were published for CLI-
in CLI than in intermittent claudication. Generally, arelated domains including pain, anxiety, depression,
statistically significant difference in total ulcer-healing,functional activity, life style, and mobility. In-
amputation rate, and/or mortality is considered clin-struments used include the Burford visual analogue
ically relevant if shown for the intention-to-treat popu-scale for pain (Burford pain thermometer), the Hos-
lation. For mortality, the same argument applies aspital Anxiety and Depression Scale, the Barthel ADL
made for PAOD stage II cardiovascular prevention(activity of daily living) Index, the Frechay Activity
trials: a statistically significant difference in cardio-Index, the Environmental Scoring System, and the
vascular mortality between groups, which also fa-Schedule for Evaluation of Individual Quality of
vourably influences all-cause mortality, should beLife. The limitations of QoL assessments discussed
acceptable.in the context of PAOD stage II patients (see Quality
of life as an endpoint section, on page 258) also apply
to CLI patients. Furthermore, QoL cannot yet be
regarded as an established endpoint in CLI trials; Acknowledgement
continued evaluation of QoL instruments is important
The Trans-Atlantic Conference on Clinical Trial Guidelines wasto define appropriate QoL measures in CLI patients.
sponsored by unrestricted educational grants from Hoechst MarionAt present QoL may be considered as a secondary Roussel, Sanofi Pharmaceuticals and Schering AG (main sponsors),
as well as Otsuka America Pharmaceuticals and Schwarz AG.endpoint in CLI trials.
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